Castration resistant metastatic disease is the major cause of morbidity and mortality in men with advanced prostate cancer. The molecular mechanisms underlying metastasis and castration resistance are both varied and only partially defined. Novel targets and therapies directed against these targets are urgently needed to combat advanced prostate cancer. Likewise, rational combination therapies directed against multiple critical targets are urgently needed. We have recently identified and

Public Health Relevance

Prostate cancer is the second leading cause of cancer-related death in the U.S. Patients with metastatic castrate resistant disease need improved treatments, particularly those who fail the newest anti-androgens. This proposal explores the role of N-cadherin as a potential novel target for advanced prostate cancer and develops a candidate antibody therapeutic that can be advanced to the clinic to manage these patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
Henning, Susanne M; Wang, Piwen; Said, Jonathan W et al. (2015) Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate 75:550-9
Apostolova, Liana G; Di, Li Jie; Duffy, Erin L et al. (2014) Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer's disease. Dement Geriatr Cogn Disord 37:315-26
Li, Z; Tseng, C-H; Li, Q et al. (2014) Clinical efficacy of a medically supervised outpatient high-protein, low-calorie diet program is equivalent in prediabetic, diabetic and normoglycemic obese patients. Nutr Diabetes 4:e105
Lin, Millicent; Chen, Jie-Fu; Lu, Yi-Tsung et al. (2014) Nanostructure embedded microchips for detection, isolation, and characterization of circulating tumor cells. Acc Chem Res 47:2941-50
Keto, Christopher J; Aronson, William J; Terris, Martha K et al. (2014) Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database. Eur Urol 65:620-7
Hsi, Eric D; Said, Jonathan; Macon, William R et al. (2014) Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project. Am J Surg Pathol 38:768-75
Wu, Anna M (2014) Engineered antibodies for molecular imaging of cancer. Methods 65:139-47
Garcia, Alejandro J; Ruscetti, Marcus; Arenzana, Teresita L et al. (2014) Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol Cell Biol 34:2017-28
Chamie, Karim; Sonn, Geoffrey A; Finley, David S et al. (2014) The role of magnetic resonance imaging in delineating clinically significant prostate cancer. Urology 83:369-75
Galet, Colette; Gollapudi, Kiran; Stepanian, Sevan et al. (2014) Effect of a low-fat fish oil diet on proinflammatory eicosanoids and cell-cycle progression score in men undergoing radical prostatectomy. Cancer Prev Res (Phila) 7:97-104

Showing the most recent 10 out of 189 publications